公开(公告)号：AU2009327357A1

公开(公告)日：2011-07-28

申请号：AU2009327357

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： JEAN-DAMIEN CHARRIER ,  STEVEN DURRANT ,  DAVID KAY ,  RONALD KNEGTEL ,  SOMHAIRLE MACCORMICK ,  MICHAEL MORTIMORE ,  MICHAEL O'DONNELL ,  JOANNE PINDER ,  ALISTAIR RUTHERFORD ,  NIZARALI VIRANI ANISA ,  STEPHEN YOUNG ,  MICHAEL REAPER PHILIP

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I):wherein the variables are as defined herein.

公开(公告)号：PT2376485T

公开(公告)日：2018-03-12

申请号：PT09798991

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： MICHAEL MORTIMORE ,  JEAN-DAMIEN CHARRIER ,  STEVEN DURRANT ,  DAVID KAY ,  RONALD KNEGTEL ,  SOMHAIRLE MACCORMICK ,  MICHAEL O'DONNELL ,  JOANNE PINDER ,  ALISTAIR RUTHERFORD ,  ANISA NIZARALI VIRANI ,  STEPHEN YOUNG ,  PHILIP MICHAEL REAPER

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

公开(公告)号：AU2009313198A1

公开(公告)日：2011-06-30

申请号：AU2009313198

申请日：2009-11-10

Applicant: VERTEX PHARMA

Inventor： JEAN-DAMIEN CHARRIER ,  STEVEN DURRANT ,  DAVID KAY ,  MICHAEL O'DONNELL ,  RONALD KNEGTEL ,  SOMHAIRLE MACCORMICK ,  JOANNE PINDER ,  ANISA VIRANI ,  STEPHEN YOUNG ,  HAYLEY BINCH ,  THOMAS CLEVELAND ,  FANNING LEV T D ,  DENNIS HURLEY ,  PRAMOD JOSHI ,  URVI SHETH ,  ALINA SILINA ,  MICHAEL REAPER PHILIP

IPC: C07D401/04 ,  A61K31/4965 ,  A61P35/00 ,  C07D403/04 ,  C07D413/04

Abstract: The present disclosure relates to pyrazine compounds of formula (I) wherein L, n, R, and R are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

公开(公告)号：BRPI0924084A2

公开(公告)日：2020-11-10

申请号：BRPI0924084

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： ALISTAIR RUTHERFORD ,  ANISA NIZARALI VIRANI ,  DAVID KAY ,  JEAN-DAMIEN CHARRIER ,  JOANNE PINDER ,  MICHAEL MORTIMORE ,  MICHAEL O'DONNELL ,  PHILIP MICHAEL REAPER ,  RONALD KNEGTEL ,  SOMHAIRLE MACCORMICK ,  STEPHEN YOUNG ,  STEVEN DURRANT

IPC: C07D401/14 ,  A61K31/497 ,  A61P35/00 ,  C07D403/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: derivados de pirazina úteis como inibidores de atr quinase, seu uso, composição farmacêutica que os compreende e método de inibir atr em uma amostra biológica. a presente invenção refere-se a compostos de pirazina úteis como inibidores de proteína atr quinase. a invenção também se refere a composições farmaceuticamente aceitáveis compreendendo os compostos desta invenção; métodos de tratamento de várias doenças, distúrbios, e condições usando os compostos desta invenção; processos para a preparação os compostos desta invenção; intermediários para a preparação dos compostos desta invenção; e métodos de uso dos compostos em aplicações in vitro, tal como o estudo de quinases em fenômenos biológicos e patológicos; o estudo de trilhas de transdução de sinal intracelular mediadas por tais quinases; e a avaliação comparativa de novos inibidores de quinase. os compostos desta invenção têm a fórmula (i), (i) em que as variáveis são como definidas aqui.